SURMOUNT-1
2022
Tirzepatide Once Weekly for the Treatment of Obesity
In 2,539 adults with obesity without type 2 diabetes, tirzepatide 5, 10 or 15 mg weekly reduced body weight at 72 weeks compared with placebo.
Result
Primary endpoint: Percent change in body weight
Weight loss −16.0/−21.4/−22.5 % vs −2.4 %; ≥20 % loss in 57 % of the 15 mg group.
- Subtopic
- Tirzepatide for obesity
- Design
- Double-blind RCT, 72 weeks
- Relevance
- Supporting: context rather than must-know.
- Source
- Jastreboff AM, et al. N Engl J Med. 2022;387(3):205-216.doi 10.1056/NEJMoa2206038
Discussion & critique
The largest pharmacological weight loss outside bariatric surgery to date, basis of the Zepbound/Mounjaro obesity indication.